A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

NCT04982549 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Stage III NSCLC

Interventions

DRUG: Durvalumab
DRUG: Carboplatin/ Paclitaxel
DRUG: Pemetrexed/ Cisplatin
DRUG: Pemetrexed/ Carboplatin
RADIATION: Radiation

Sponsor

Shandong Cancer Hospital and Institute